Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines

Kshitij Verma, Tianzhu Zang, Nehal Gupta, Trevor M. Penning, Paul C. Trippier

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We report the design, synthesis, and evaluation of potent and selective inhibitors of aldo-keto reductase 1C3 (AKR1C3), an important enzyme in the regulatory pathway controlling proliferation, differentiation, and apoptosis in myeloid cells. Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by >10-fold. The results validate AKR1C3 inhibition as a common adjuvant target across multiple AML subtypes. These compounds in coadministration with chemotherapeutics in clinical use enhance therapeutic index and may avail chemotherapy as a treatment option to the pediatric and geriatric population currently unable to tolerate the side effects of cancer drug regimens.

Original languageEnglish (US)
Pages (from-to)774-779
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume7
Issue number8
DOIs
StatePublished - Aug 11 2016

Fingerprint

Myeloid Cells
Acute Myeloid Leukemia
Daunorubicin
Cells
Etoposide
Cytotoxicity
Cell Line
Geriatrics
Pediatrics
Chemotherapy
Therapeutic Uses
Drug-Related Side Effects and Adverse Reactions
Apoptosis
Drug Therapy
Enzymes
Therapeutics
Pharmaceutical Preparations
Population
carbonyl reductase (NADPH)
Neoplasms

Keywords

  • AKR1C3 Inhibitor
  • acute myeloid leukemia
  • adjuvant
  • daunorubicin
  • etoposide
  • synergism

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Organic Chemistry

Cite this

Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. / Verma, Kshitij; Zang, Tianzhu; Gupta, Nehal; Penning, Trevor M.; Trippier, Paul C.

In: ACS Medicinal Chemistry Letters, Vol. 7, No. 8, 11.08.2016, p. 774-779.

Research output: Contribution to journalArticle

@article{1cf077684db34695b19a0d4f0281806d,
title = "Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines",
abstract = "We report the design, synthesis, and evaluation of potent and selective inhibitors of aldo-keto reductase 1C3 (AKR1C3), an important enzyme in the regulatory pathway controlling proliferation, differentiation, and apoptosis in myeloid cells. Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by >10-fold. The results validate AKR1C3 inhibition as a common adjuvant target across multiple AML subtypes. These compounds in coadministration with chemotherapeutics in clinical use enhance therapeutic index and may avail chemotherapy as a treatment option to the pediatric and geriatric population currently unable to tolerate the side effects of cancer drug regimens.",
keywords = "AKR1C3 Inhibitor, acute myeloid leukemia, adjuvant, daunorubicin, etoposide, synergism",
author = "Kshitij Verma and Tianzhu Zang and Nehal Gupta and Penning, {Trevor M.} and Trippier, {Paul C.}",
year = "2016",
month = "8",
day = "11",
doi = "10.1021/acsmedchemlett.6b00163",
language = "English (US)",
volume = "7",
pages = "774--779",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines

AU - Verma, Kshitij

AU - Zang, Tianzhu

AU - Gupta, Nehal

AU - Penning, Trevor M.

AU - Trippier, Paul C.

PY - 2016/8/11

Y1 - 2016/8/11

N2 - We report the design, synthesis, and evaluation of potent and selective inhibitors of aldo-keto reductase 1C3 (AKR1C3), an important enzyme in the regulatory pathway controlling proliferation, differentiation, and apoptosis in myeloid cells. Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by >10-fold. The results validate AKR1C3 inhibition as a common adjuvant target across multiple AML subtypes. These compounds in coadministration with chemotherapeutics in clinical use enhance therapeutic index and may avail chemotherapy as a treatment option to the pediatric and geriatric population currently unable to tolerate the side effects of cancer drug regimens.

AB - We report the design, synthesis, and evaluation of potent and selective inhibitors of aldo-keto reductase 1C3 (AKR1C3), an important enzyme in the regulatory pathway controlling proliferation, differentiation, and apoptosis in myeloid cells. Combination treatment with the nontoxic AKR1C3 inhibitors and etoposide or daunorubicin in acute myeloid leukemia cell lines, elicits a potent adjuvant effect, potentiating the cytotoxicity of etoposide by up to 6.25-fold and the cytotoxicity of daunorubicin by >10-fold. The results validate AKR1C3 inhibition as a common adjuvant target across multiple AML subtypes. These compounds in coadministration with chemotherapeutics in clinical use enhance therapeutic index and may avail chemotherapy as a treatment option to the pediatric and geriatric population currently unable to tolerate the side effects of cancer drug regimens.

KW - AKR1C3 Inhibitor

KW - acute myeloid leukemia

KW - adjuvant

KW - daunorubicin

KW - etoposide

KW - synergism

UR - http://www.scopus.com/inward/record.url?scp=84982182484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982182484&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.6b00163

DO - 10.1021/acsmedchemlett.6b00163

M3 - Article

C2 - 27563402

AN - SCOPUS:84982182484

VL - 7

SP - 774

EP - 779

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 8

ER -